FDA Hold Has ZFGN Eyeing Worst Day in Years

Zafgen stock is plummeting on concerns about its diabetes treatment

Nov 26, 2018 at 10:17 AM

ZFGN

Shares of Zafgen Inc (NASDAQ:ZFGN) are getting destroyed this morning, after the Food and Drug Administration (FDA) put a clinical hold on a trial of the company's experimental diabetes treatment, citing heart safety risks. The company plans to request a meeting with the FDA to go over next steps for ZGN-1061.

Zafgen stock was last seen 44.5% lower at $5.05 -- in territory not charted since January. The shares are pacing for their worst day since July 2016, and are back below their 200-day moving average for the first time in 2018. Prior to today, the equity had been up about 100% year-to-date, with pullbacks contained by its 32-week moving average.

ZFGN is also on the short-sale restricted list today. Nevertheless, several shorts are likely cheering today's plummet. Short interest on the stock represents more than a week's worth of trading, at Zafgen's average daily volume.

Meanwhile, the equity could be vulnerable to negative analyst notes. Half of the four analysts following the stock maintain "strong buy" opinions, and the average 12-month price target of $13.20 represents upside of more than 160% from current levels

Follow @Schaeffers

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!